Advertisement

Wiener klinische Wochenschrift

, Volume 127, Issue 3–4, pp 98–102 | Cite as

Ki-67 proliferation index in patients with placenta previa percreta in the third trimester

  • Nese HilaliEmail author
  • Sezen Kocarslan
  • Mehmet Vural
  • Adnan Incebiyik
  • Aysun Camuzcuoglu
  • Hakan Camuzcuoglu
original article

Abstract

Aim

The purpose of this study was to investigate proliferative capacity of placenta previa percreta in the third trimester via evaluating Ki-67 proliferating index.

Methods

The paraffin blocks of placental tissues, which were obtained from the patients who underwent hysterectomy for placenta previa percreta (n = 12, gestational age > 28 weeks), from legal abortions (n = 12, gestational age < 10 weeks), and of cesarean deliveries with the indication of previous cesarean section, without any complication (n = 12, gestational age > 38 weeks), between January 2011 and April 2013, were included into the study. The paraffin blocks of the patients were stained with Ki-67 (proliferating cell marker) immunohistochemically, and Ki-67 proliferation index levels were calculated.

Results

Ki-67 proliferation index levels were higher in patients with legal abortions than patients with placenta percreta or noncomplicated cesarean delivery group. However, any statistically significant difference was not detected between the percreta and noncomplicated groups (p > 0.05).

Conclusion

The tissue samples of the patients with placenta previa percreta exhibited low proliferative capacity similar to the samples of normal placentation group.

Keywords

Ki-67 Proliferation index Placenta Previa percreta 

Ki-67 Proliferationsindex bei Patientinnen mit Placenta praevia percreta im dritten Trimester

Zusammenfassung

Ziel der Studie

war es, die proliferative Kapazität einer Placenta praevia percreta im 3. Trimester durch Erhebung des Ki-67 Proliferations-Indexes zu evaluieren.

Methoden

Paraffinblöcke von Placentagewebe, welches von Frauen stammte, die wegen Placenta praevia percreta (n = 12, Gestationsalter > 28 Wochen), wegen legalen Abortus (n = 12; Gestationsalter < 10 Wochen), bzw. wegen indizierter komplikationsloser Sectio cesarea (n = 12; Gestationsalter > 38 Wochen) im Zeitraum Jänner 2011 bis April 2013 hysterektomiert worden waren, wurden untersucht. Die Blöcke wurden mit Ki-67 (Marker der Zellproliferation) immunhistochemisch gefärbt. Die Ki-67 Proliferationsindexhöhen wurden errechnet.

Ergebnisse

Die Ki-67 Proliferationsindices waren in den Placentas der Frauen mit legalem Abortus höher als bei den Frauen mit Placenta percreta beziehungsweise mit Kaiserschnitt. Es konnte allerdings kein statistisch signifikanter Unterschied der bei Placenta percreta erhobenen Werte und der bei den anderen Gruppen erhobenen Werte festgestellt werden (p > 0,05).

Schlussfolgerungen

Gewebeproben von Placentas von Frauen mit Placenta praevia percreta zeigten eine niedrige Proliferationskapzität, die der Proliferation von normalen Placentas ähnlich war.

Schlüsselwörter

Ki-67 Proliferationsindex Placenta Praevia Percreta 

References

  1. 1.
    Wu S, Kocherginsky M, Hibbard JU. Abnormal placentation: twenty-year analysis. Am J Obstet Gynecol. 2005;192(5):1458–61.CrossRefPubMedGoogle Scholar
  2. 2.
    Zepiridis L, Zafrakas M, Theodoridis TD, et al. Human placental lactogen and color doppler in predicting expulsion of retained adherent placenta: a new clinical observation. Arch Gynecol Obstet. 2009;280(6):1041–4. doi:10.1007/s00404-009-1045-9.CrossRefPubMedGoogle Scholar
  3. 3.
    Clément D, Kayem G, Cabrol D. Conservative treatment of placenta percreta: a safe alternative. Eur J Obstet Gynecol Reprod Biol. 2004;114(1):108–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Ferretti C, Bruni L, Dangles-Marie V, et al. Molecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblasts. Hum Reprod Update. 2006;13(2):121–41.CrossRefPubMedGoogle Scholar
  5. 5.
    Khan M, Sachdeva P, Arora R, et al. Conservative management of morbidly adherant placenta—a case report and review of literature. Placenta. 2013;34(10):963–6. doi:10.1016/j.placenta.2013.04.016.CrossRefPubMedGoogle Scholar
  6. 6.
    Steins Bisschop CN, Schaap TP, Vogelvang TE, et al. Invasive placentation and uterus preserving treatment modalities: a systematic review. Arch Gynecol Obstet. 2011;284(2):491–502. doi:10.1007/s00404-011-1934-6.CrossRefPubMedCentralPubMedGoogle Scholar
  7. 7.
    Barber JT Jr., Tressler TB, Willis GS, et al. Arteriovenous malformation identification after conservative management of placenta percreta with uterine artery embolization and adjunctive therapy. Am J Obstet Gynecol. 2011;204(5):e4–8. doi:10.1016/j.ajog.2011.01.001.CrossRefPubMedGoogle Scholar
  8. 8.
    Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311–22.CrossRefPubMedGoogle Scholar
  9. 9.
    Tantbirojn P, Crum CP, Parast MM. Pathophysiology of placenta creta: the role of decidua and extravillous trophoblast. Placenta. 2008;29(7):639–45. doi:10.1016/j.placenta.2008.04.008.CrossRefPubMedGoogle Scholar
  10. 10.
    Tseng JJ, Hsu SL, Ho ES, et al. Differential expression of angiopoietin-1, angiopoietin-2, and Tie receptors in placentas from pregnancies complicated by placenta accreta. Am J Obstet Gynecol. 2006;194(2):564–71.CrossRefPubMedGoogle Scholar
  11. 11.
    Wehrum MJ, Buhimschi IA, Salafia C, et al. Accreta complicating complete placenta previa is characterized by reduced systemic levels of vascular endothelial growth factor and by epithelial-to-mesenchymal transition of the invasive trophoblast. Am J Obstet Gynecol. 2011;204(5):411.e1–11. doi:10.1016/j.ajog.2010.12.027.CrossRefPubMedCentralPubMedGoogle Scholar
  12. 12.
    Kim KR, Jun SY, Kim JY, et al. Implantation site intermediate trophoblasts in placenta cretas. Mod Pathol. 2004;17:1483–90.CrossRefPubMedGoogle Scholar
  13. 13.
    Stanek J, Drummond Z. Occult placenta accreta: the missing link in the diagnosis of abnormal placentation. Pediatr Dev Pathol. 2007;10:266–73.CrossRefPubMedGoogle Scholar
  14. 14.
    Cramer SF. Letter to the editor: case report. Pediatr Pathol. 1987;7:473–5.CrossRefPubMedGoogle Scholar
  15. 15.
    Skubisz MM, Tong S. The evolution of methotrexate as a treatment for ectopic pregnancy and gestational trophoblastic neoplasia: a review. ISRN Obstet Gynecol. 2012;2012:637094. doi:10.5402/2012/637094.CrossRefPubMedCentralPubMedGoogle Scholar
  16. 16.
    Samra ZQ, Ahmad S, Javeid M, et al. Anticancer medicines (doxorubicin and methotrexate) conjugated with magnetic nanoparticles for targeting drug delivery through iron. Prep Biochem Biotechnol. 2013;43(8):781–97. doi:10.1080/10826068.2013.782042.CrossRefPubMedGoogle Scholar
  17. 17.
    Stitely ML, Gerard Jackson M, Holls WH. Log-linear human chorionic gonadotropin elimination in cases of retained placenta percreta. Arch Gynecol Obstet. 2013. doi:10.1007/s00404-013-2950-5.Google Scholar
  18. 18.
    Sentilhes L, Ambroselli C, Kayem G, et al. Maternal outcome after conservative treatment of placenta accreta. Obstet Gynecol. 2010;115(3):526–34.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2014

Authors and Affiliations

  • Nese Hilali
    • 1
    Email author
  • Sezen Kocarslan
    • 2
  • Mehmet Vural
    • 1
  • Adnan Incebiyik
    • 1
  • Aysun Camuzcuoglu
    • 1
  • Hakan Camuzcuoglu
    • 1
  1. 1.Faculty of Medicine, Department of Gynecology and ObstetricsHarran University School of MedicineSanliurfaTurkey
  2. 2.Faculty of Medicine, Department of PathologyHarran UniversitySanliurfaTurkey

Personalised recommendations